First-in-human experience of CXCR4-directed endoradiotherapy with 177Lu-and 90Y-labeled pentixather in advanced-stage multiple myeloma with extensive intra-and extramedullary disease

Ken Herrmann, Margret Schottelius, Constantin Lapa, Theresa Osl, Andreas Poschenrieder, Heribert Hänscheid, Katharina Lückerath, Martin Schreder, Christina Bluemel, Markus Knott, Ulrich Keller, Andreas Schirbel, Samuel Samnick, Michael Lassmann, Saskia Kropf, Andreas K. Buck, Hermann Einsele, Hans Juergen Wester, Stefan Knop

Research output: Contribution to journalArticlepeer-review

191 Scopus citations

Abstract

Chemokine receptor 4 (CXCR4) is a key factor for tumor growth and metastasis in several types of human cancer. Based on promising experiences with a radiolabeled CXCR4 ligand (68Ga-pentixafor) for diagnostic receptor targeting, 177Lu-and 90Y-pentixather were recently developed as endoradiotherapeutic vectors. Here, we summarize the first-in-human experience in 3 heavily pretreated patients with intramedullary and extensive extramedullary manifestations of multiple myeloma undergoing CXCR4-directed endoradiotherapy. Methods: CXCR4 target expression was demonstrated by baseline 68Ga-pentixafor PET. Each treatment was approved by the clinical ethics committee. Pretherapeutic 177Lu-pentixather dosimetry was performed before 177Lu-pentixather or 90Y-pentixather treatment. Subsequently, patients underwent additional chemotherapy and autologous stem cell transplantation for bone marrow rescue. Results: A remarkable therapeutic effect was visualized in 2 patients, who showed a significant reduction in 18F-FDG uptake. Conclusion: CXCR4-targeted radiotherapy with pentixather appears to be a promising novel treatment option in combination with cytotoxic chemotherapy and autologous stem cell transplantation, especially for patients with advanced multiple myeloma.

Original languageEnglish
Pages (from-to)248-251
Number of pages4
JournalJournal of Nuclear Medicine
Volume57
Issue number2
DOIs
StatePublished - 1 Feb 2016

Keywords

  • CXCR4
  • Endoradiotherapy
  • Multiple myeloma
  • Pentixather

Fingerprint

Dive into the research topics of 'First-in-human experience of CXCR4-directed endoradiotherapy with 177Lu-and 90Y-labeled pentixather in advanced-stage multiple myeloma with extensive intra-and extramedullary disease'. Together they form a unique fingerprint.

Cite this